

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/025652 A1

(51) International Patent Classification⁷: **A61M 5/46**

(21) International Application Number:
PCT/US2004/027961

(22) International Filing Date: 26 August 2004 (26.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/656,491 5 September 2003 (05.09.2003) US

(71) Applicant (for all designated States except US): **ADVANCED CARDIOVASCULAR SYSTEMS, INC.**
[US/US]; 3200 Lakeside Drive, Santa Clara, CA 95054 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BEYERLEIN, Dagmar** [DE/US]; 74 Mountain Spring Avenue, San Francisco, CA 94114 (US).

(74) Agents: **SCHELLER, James, C.** et al.; Blakely, Sokoloff, Taylor & Zafman LLP, 12400 Wilshire Boulevard, 7th Floor, Los Angeles, CA 90025 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GI, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SYSTEMS AND METHODS FOR DETECTING TISSUE CONTACT AND NEEDLE PENETRATION DEPTH USING STATIC FLUID PRESSURE MEASUREMENTS



(57) Abstract: Systems and methods for determining tissue contact and penetration depth are provided. In one aspect, the system includes a needle and a pressure measurement assembly. The needle, in one exemplary embodiment, includes a first end and a second end with at least one aperture located a predetermined distance from the first end. The fluid pressure measurement assembly is connected with a portion of the needle to measure pressure of fluid dispensed in the needle. The fluid pressure measurement assembly measures a first pressure of the fluid, a second pressure when the needle contacts tissue and a third pressure when the needle penetrates the tissue and the aperture becomes occluded.



WO 2005/025652 A1

-1-

**SYSTEMS AND METHODS FOR DETECTING TISSUE CONTACT AND
NEEDLE PENETRATION DEPTH
USING STATIC FLUID PRESSURE MEASUREMENTS**

RELATED APPLICATION

[0001] This is a continuation in part of U.S. Patent Application Number 10/166,854, filed on June 10, 2002. The Application 10/166,854 is hereby incorporated by reference in its entirety.

FIELD

[0002] The invention relates generally to needles, and more particularly, to a system and method for detecting tissue contact and needle penetration depth.

BACKGROUND

[0003] Drug delivery systems currently exist that supply therapeutic substances through a needle to regions of a patient's body. Such regions may include a diseased blood vessel, body cavity or organ. In the case of a diseased blood vessel, for example, the therapeutic agent may be used to treat an arterial lesion and/or to promote an angiogenic response

[0004] In some applications, a needle may be connected to a catheter assembly to deliver the therapeutic agent deep into the body. In this application, it is often difficult to determine when the needle contacts the organ, cavity wall, or vessel wall. Further, it is difficult to determine the penetration depth of the needle. In many of the applications for which a needle catheter assembly is used to deliver therapeutic agents to regions within the body, the agent must be delivered to a precise location. Accordingly, it is desirable to provide feedback that indicates when the needle contacts the cavity or vessel wall and when the needle has been inserted to a predetermined depth.

SUMMARY

[0005] Systems and methods for determining tissue contact and penetration depth are provided. In one aspect, the system includes a needle and a fluid pressure measurement assembly. The needle, in one exemplary embodiment, includes a first end and a second end with at least one aperture located a predetermined distance from the first end. The fluid pressure measurement assembly is connected with a portion of the needle to measure pressure of fluid dispensed in the needle. The fluid pressure measurement assembly measures a first pressure with the fluid dispensed in the needle, a second pressure when the needle contacts the tissue and begins to compress the fluid in the needle and a third pressure when the needle penetrates the tissue further compressing the fluid in the needle, and the aperture becomes occluded.

[0006] In an alternative aspect, the system includes a needle and a fluid pressure sensor. The fluid pressure sensor, in another exemplary embodiment, is coupled with a portion of the needle. The needle, in one exemplary embodiment, includes a first end and a second end with at least one aperture located a predetermined distance from the first end. The sensor is connected with a portion of the needle to allow for measurement of pressure of fluid dispensed in the needle. The sensor allows for measurement of a first pressure with the fluid dispensed in the needle, a second pressure when the needle contacts the tissue and begins to compress the fluid in the needle and a third pressure when the needle penetrates the tissue further compressing the fluid in the needle, and the aperture becomes occluded. The fluid pressure sensor is located a predetermined distance from the first end of the needle.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] The present invention is illustrated by way of example, and not limitation, in the figures of the accompanying drawings in which:

-3-

[0008] Figure 1 illustrates a side cross-sectional view of one embodiment of a fluid delivery catheter;

[0009] Figure 2 illustrates the embodiment of the fluid delivery catheter of Figure 1 where the needle penetrates tissue;

[0010] Figure 2a illustrates an alternative embodiment of a fluid delivery catheter where a needle penetrates and extends into tissue beyond the vessel wall;

[0011] Figures 3a-3c illustrate the embodiment of the fluid delivery catheter of Figure 1 in different positions with respect to the tissue;

[0012] Figure 4 illustrates a graph representing different fluid injection pressure measurements within the needle corresponding to various positions of the needle with respect to the tissue as shown in Figures 3a-3c where the fluid is constantly being injected through the needle as it is being advanced;

[0013] Figure 5 illustrates a graph representing different static fluid pressure measurements within the needle corresponding to various positions of the needle with respect to the tissue as shown in Figures 3a-3c where the fluid is static (e.g., not flowing) through the needle as it is being advanced;

[0014] Figure 6 illustrates a front view of one assembly for measuring the pressure of the fluid in the needle;

[0015] Figure 7 illustrates a front view of an alternative assembly for measuring the pressure of the fluid in the needle;

[0016] Figure 8 illustrates an exemplary circuit scheme that can be incorporated into a pressure measuring assembly to measure changes in pressure;

[0017] Figure 9 illustrates a visual indicator that can be incorporated into a pressure measuring assembly to indicate the position of the needle;

[0018] Figure 10 illustrates a side cross-sectional view of an embodiment of a fluid delivery catheter with a force transducer;

[0019] Figures 10a and 10b illustrate the embodiment of the fluid delivery catheter of Figure 10 in different positions with respect to the tissue;

-4-

[0020] Figure 11 illustrates an enlarged view of the embodiment of the needle and the force transducer shown in Figure 10;

[0021] Figure 12a illustrates an enlarged view of an alternative embodiment of a needle for use in the fluid delivery catheter shown in Figure 10;

[0022] Figure 12b illustrates an enlarged view of an alternative embodiment of a force transducer for use in the fluid delivery catheter shown in Figure 10;

[0023] Figure 12c illustrates an enlarged view of the needle of Figure 9a and the force transducer of Figure 12b;

[0024] Figure 13 illustrates a front view of one embodiment of a piezoelectric force transducer connected to the second end of a needle;

[0025] Figure 14 illustrates a flow diagram of one embodiment of a process for detecting tissue contact and needle penetration depth; and

[0026] Figure 15 illustrates another flow diagram of one embodiment of a process for detecting tissue contact and needle penetration depth.

DETAILED DESCRIPTION

[0027] Systems and methods for detecting tissue contact and needle penetration depth are described. In the following detailed description of the present invention, numerous specific details are set forth in order to provide a thorough understanding of the present invention. However, it will be apparent to one skilled in the art that the present invention may be practiced without these specific details. In some instances, well-known structures and devices are shown in block diagram form, rather than in detail, in order to avoid obscuring the present invention. Several exemplary embodiments are described herein, and it will be appreciated that alternative embodiments exist within the scope of this invention.

[0028] Figure 1 illustrates a side cross sectional view of one embodiment of a fluid delivery catheter 100. The fluid delivery catheter 100 can be used to provide therapeutic agents to a particular region of a patient's body, for example,

-5-

to prevent or treat arterial disease (e.g. arterial stenosis or restenosis). The fluid delivery catheter 100 can be any medical device designed for insertion into a region of a patient's body to permit injection of fluids. It is contemplated that the fluid delivery catheter has applicability for use with any region within a patient's body, including blood vessels (e.g. coronary arteries), blood vessel wall, cardiac muscle, urinary tract, intestinal tract, kidney ducts, and other sites.

[0029] In Figure 1, the fluid delivery catheter 100 includes a needle 130 within a needle sheath 110. The needle sheath is mounted on a dilatation catheter 120. The fluid delivery catheter 100 is shown within a cavity 160 of a patient's body in Figure 1. The cavity 160 may be a lumen of a blood vessel, such as a coronary artery, or cardiac tissue. The fluid delivery catheter 100 is maneuvered over a guidewire 114. The guidewire directs the fluid delivery catheter 100 through torturous passageways within the body to arrive at the desired body cavity 160. The dilatation catheter 120 has a balloon 112 that inflates and directs the needle tip 132, which is extendable, toward body tissue such as a blood vessel wall 150.

[0030] The needle 130 includes a needle tip 132 and an aperture 134 located a predetermined distance from the needle tip 132. As the needle 130 is inserted into body tissue, first the needle tip 132 lumen and then the aperture 134 become occluded. This is shown in Figure 2. The occlusion of the needle tip 132 lumen and aperture 134 increase the injection pressure of the fluid within the needle 130, thereby allowing an operator to determine tissue contact and penetration depth of the needle 130.

[0031] In one embodiment, the fluid is constantly flowing through the needle 130 as the needle 130 is being advanced into the body tissue. The dynamic injection pressure of the fluid is measured. With the fluid constantly flowing through the needle 130, the fluid dynamic injection pressure changes (increases) as the needle tip 132 lumen contacts the body tissue, and changes (increases) again when the aperture 134 becomes occluded. The changes in the fluid

dynamic injection pressure indicate the changes in the penetration depth of the needle 130.

[0032] In another embodiment, the fluid is dispensed into the needle 130 but not constantly flowing through the needle 130 as the needle 130 is being advanced into the body tissue. The static pressure of the fluid is measured. With the fluid dispensed in the needle 130, a first static pressure is measured. As the needle tip 132 lumen contacts the body tissue, the tissue compresses the fluid within the needle and the static pressure changes (increases) resulting in a second static pressure measurement. As the needle 130 penetrates deeper into the body tissue and the aperture 134 becomes occluded, the static pressure changes (increases) resulting in a third static pressure measurement. The changes in the static fluid pressure (from the first, to second and to the third pressure) indicate the changes in the penetration depth of the needle 130.

[0033] In one embodiment the needle 130 may include more than one aperture 134 spaced in predetermined distances from the needle tip new number of the needle 130. For example, a first aperture 134 may be located a first predetermined distance from the needle tip 132. A second aperture (not shown) may be located a second predetermined distance from the first aperture 134. In alternative embodiments, there may be more than two apertures.

[0034] In one embodiment, the space between the apertures may be the same. In other alternative embodiments, the distances between the apertures may be different. In another embodiment, the apertures may all be the same size and shape while in another embodiment the sizes and shapes of the apertures could be different. The apertures should be much smaller than the needle tip 132 lumen so that the fluid will be ejected from the needle tip 132 lumen rather than the aperture 134. In one embodiment, the occlusion of both the needle tip 132 lumen and individual aperture 134 and the concomitant increases of fluid pressure allow an operator to determine the penetration depth of the needle 130 as it becomes embedded in the vessel wall 150. The fluid pressure includes the

-7-

dynamic pressure and the static pressure of the fluid depending on the embodiments. In embodiments where the fluid is constantly flowing through the needle 130 as the needle 130 is advanced into the body tissue, the pressure changes indicate the changes in the dynamic injection pressure of the fluid. In embodiments where the fluid is dispensed through the needle 130 prior to the injection and the fluid is static (e.g., not flowing) through the needle 130 as the needle 130 is advanced into the body tissue, the pressure changes indicate the changes in the static pressure of the fluid as the tissue compresses the fluid in the needle 130. The changes the static fluid pressure or the injection dynamic pressure allow an operator to determine the penetration depth of the needle 130 as it becomes embedded in the vessel wall 150.

[0035] Figure 2 illustrates the embodiment of the fluid delivery catheter 100 of Figure 1 where the needle 130 is shown penetrating a vessel wall 150. As the needle tip 132 contacts the vessel wall 150, the needle tip 132 lumen becomes occluded. Then, as the needle 130 further penetrates the vessel wall 150, the aperture 134 that is located a predetermined distance from the needle tip 132 becomes occluded. Accordingly, in alternative embodiments, the predetermined distance between the needle tip 132 and aperture 134 may vary according to what the desired penetration depth may be.

[0036] In one embodiment, injection pressure measurements are taken continuously as a therapeutic agent is injected from the first end of a needle, through the needle 130, and through the needle tip 132 lumen. The pressure measurements indicate the dynamic injection pressures of the therapeutic agent as the needle 130 is advancing into the tissue. The changes in the dynamic injection pressure indicate the penetration depth of the needle 130.

[0037] In an alternative embodiment, a first static fluid pressure is measured when the needle 130 is filled with a therapeutic agent; a second static fluid pressure is measured when the needle tip 132 contacts the vessel wall 150 and as the needle tip 132 lumen becomes occluded; and a third static fluid pressure is

-8-

measured when the needle 130 advances further into the vessel wall 150 and the aperture 134 becomes occluded. The therapeutic agent is not injected continuously as the needle 130 is being advanced. The pressure measurements indicate the static fluid pressure of the therapeutic agent as the needle 130 is advancing into the tissue. The changes in the static pressure caused by the compression of the fluid by the tissue indicate the penetration depth of the needle 130.

[0038] As the vessel wall or other tissue within the body occludes the needle tip 132 lumen, an increase in pressure will occur. Accordingly, an operator is able to determine by the increase in fluid pressure that the needle tip 132 has contacted the vessel wall. As the vessel wall or other tissue occludes the aperture 134, another increase in fluid pressure will occur. An operator is again able to determine by the second increase in pressure that the needle 130 has been inserted to a predetermined depth in the tissue or vessel wall 150.

[0039] Figure 2A illustrates an alternative embodiment of a fluid delivery catheter 200 where a needle 230 penetrates and extends into tissue 270 beyond the vessel wall 250. In Figure 2A, the needle 230 includes more than one aperture. The first aperture 234 is located a predetermined distance from the needle tip 232 so that occlusion of the first aperture 234 indicates penetration of the needle 230 a certain depth into the first tissue layer or vessel wall 250. The second aperture 236 is located a predetermined distance from the first aperture 234 so that the occlusion of the second aperture 236 indicates a further penetration of the needle 230. In some cases, an operator may have knowledge about the thickness of certain tissue. For example, the vessel wall 250 may be a known thickness. The second aperture 236 may then be placed according to that known thickness so that occlusion of the second aperture 236 indicates the needle 230 has penetrated all the way through the first layer of tissue 250 and into the second layer of tissue 270.

[0040] Figures 3A-3C illustrate an embodiment of the fluid delivery catheter 100 in different positions with respect to the vessel wall 150. Figure 3A illustrates the fluid delivery catheter 100 where the needle 130 has not yet contacted the vessel wall 150. The needle tip 132 is close to and proximate to but not contacting the vessel wall 150. In one embodiment, a therapeutic agent is dispensed in the needle 130 prior to the penetration of the needle 130 into the vessel wall 150. The therapeutic agent is not continuously injected through the needle 130 as the needle 130 is being advanced in this embodiment. As shown in Figure 3A, the needle 130 has not yet contacted the vessel wall 150. The initial pressure of therapeutic agent can be taken to indicate the first static fluid pressure.

[0041] Figure 3B illustrates the fluid delivery catheter 100 where a portion of the needle tip 132 lumen is contacting and has become embedded in the vessel wall 150. However, the needle 130 has not been fully inserted into the vessel 150. Accordingly, as seen in Figure 3B, the desired penetration depth of the needle 130 has not been achieved. In the embodiment where the therapeutic agent is dispensed in the needle 130 prior to the penetration of the needle 130 into the vessel wall 150 and not continuously being injected through the needle 130 as the needle 130 is being advanced, as the needle tip 132 lumen contacts and becomes embedded in the vessel wall 150, the tissue compresses the fluid and the static fluid pressure increases to a second static fluid pressure. The increase in the static fluid pressure indicates to the operator that the needle tip 132 lumen has penetrated the vessel wall 150 but that the desired penetration depth has not been achieved.

[0042] Figure 3C illustrates the fluid delivery catheter 100 where the needle 130 has penetrated the vessel wall 150 to a predetermined depth. The desired penetration depth has been achieved when the vessel wall 150 tissue occludes the aperture 134. As seen in Figure 3C, both the needle tip 132 lumen and the aperture 134 are embedded within the vessel wall 150. Accordingly, as

-10-

discussed above, an operator is able to determine by the increase in static fluid pressure caused by the occlusion of the aperture 134 that the needle 130 has penetrated the tissue to a predetermined depth. In the embodiment where the therapeutic agent is dispensed in the needle 130 prior to the penetration of the needle 130 into the vessel wall 150 and not continuously being injected through the needle 130 as the needle 130 is being advanced, as the aperture 134 contacts and becomes embedded in the vessel wall 150, the static fluid pressure increases to a third static fluid pressure. The increase in the static fluid pressure indicates to the operator that the needle tip 132 lumen has penetrated the vessel wall 150 and the aperture 134 has become occluded and that the desired penetration depth has been achieved.

[0043] Figure 4 illustrates a graph representing different pressure measurements of fluid within the needle 130 taken at the three needle positions shown in Figures 3A through 3C. In one embodiment, the pressure measurements are dynamic measurements of injection pressure. A therapeutic agent is continuously and constantly injected through the needle 130 as the needle 130 is being advanced into the vessel wall 150. The graph is representative of pressure versus time where it is assumed that the needle 130 is pushed into vessel wall 150 over time in the sequence shown in Figures 3A (first), 3B (next), and 3C (last). As the needle 130 is in the body cavity 160 as seen in Figure 3A but not contacting the vessel wall 150, the injection pressure is lower than the scenarios shown in Figures 3B and 3C. This pressure measurement is shown as region A 410 in Figure 4. As a portion of the needle tip 132 penetrates the vessel wall 150, an increase in dynamic injection pressure occurs. The pressure increases dramatically after the needle tip lumen 132 becomes occluded, but the rate decreases slightly shortly thereafter as shown in region B 420 in Figure 4. As the needle 130 penetrates the tissue or the vessel wall 150 a predetermined depth and the aperture 134 becomes occluded, a second dramatic increase in injection pressure is detected. This pressure spike is

-11-

shown as region C 430 in Figure 4. Although only 3 points are shown in Figure 4 corresponding to Figures 3A 3B and 3C, if additional apertures were to be added on the needle, additional pressure increases would occur as each aperture became occluded.

[0044] Figure 5 illustrates a graph representing different pressure measurements of fluid within the needle 130 taken at the three needle positions shown in Figures 3A through 3C. In one embodiment, the pressure measurements are static fluid pressure measurements. The needle 130 is filled with a therapeutic agent but the therapeutic agent is not continuously injected through the needle 130. Three graphs are illustrated in Figure 5, one for each time the needle 130 penetrates into the vessel wall 150. The therapeutic agent may be different each time. Alternatively, the vessel wall 150 may be of different types, for example, the vessel wall 150 may be a cardiac tissue. The vessel wall 150 may be any type of tissue.

[0045] In one embodiment, the graphs are representative of pressure versus time where it is assumed that the needle 130 is pushed into vessel wall 150 over time in the sequence shown in Figures 3A (first), 3B (next), and 3C (last). As the needle 130 is in the body cavity 160 as seen in Figure 3A but not contacting the vessel wall 150, the static fluid pressure is lower than the scenarios shown in Figures 3B and 3C. This static fluid pressure measurement is shown as region 310, 320, or 330 in Figure 5. As a portion of the needle tip 132 lumen penetrates the vessel wall 150, an increase in static fluid pressure occurs. The tissue from vessel wall 150 occludes the needle tip 132 lumen beginning with the needle tip 132 and compresses the therapeutic agent in the needle 130. The static fluid pressure increases dramatically after the needle tip 132 lumen becomes occluded as shown in region 312, 322, or 332. The rate decreases slightly shortly thereafter as shown in region 314, 324, or 334 in Figure 5. As the needle 130 penetrates the tissue or the vessel wall 150 a predetermined depth and the aperture 134 becomes occluded, a second dramatic increase in static fluid

-12-

pressure is detected. The tissue from the vessel wall 150 occludes the aperture 134 as well as the needle lumen thus exerting even more pressure on the therapeutic agent in the needle 130. This pressure spike is shown as region 316, 326, or 336 in Figure 5. Although only 3 points are shown in Figure 5, if additional apertures were to be added on the needle, additional pressure increases would occur as each aperture became occluded.

[0046] Figure 6 illustrates a front view of one embodiment of a fluid pressure measurement assembly 500 connected to a needle 130. In one embodiment, as shown in Figure 6, the fluid pressure measurement assembly 500 includes a sensor 512 to measure fluid pressure.

[0047] As seen in Figure 6, one end of the pressure measurement assembly 500 is connected to a syringe 514. In one embodiment, a syringe pump 612 in Figure 7 is used to inject the fluid from the syringe 514 and through the needle 130 at a constant, controlled rate. In another embodiment, the syringe pump 612 is not necessary. The needle 130 may be filled with the fluid prior to use by any convenient method. In one embodiment, it is preferable to not have the fluid constantly being pumped through the needle 130.

[0048] In one embodiment, the sensor 512 detects a first fluid injection pressure increase as the needle tip contacts tissue. The sensor 512 measures a second fluid injection pressure increase as the needle 130 penetrates the tissue to a predetermined depth. The second fluid injection pressure increase occurs as the aperture in the needle (shown in Figures 1-3) becomes occluded, thereby increasing the fluid injection pressure of the therapeutic agent being injected into the tissue.

[0049] In another embodiment, the sensor 512 detects a first static fluid pressure of the fluid in the needle 130. The sensor 512 also detects a second static fluid pressure as the needle tip 132 lumen contacts the tissue. The sensor 512 also determines the static fluid pressure change between the first and the second static fluid pressure (an increase in pressure) to indicate that the needle

-13-

tip 132 lumen has contacted the tissue and has become occluded. The sensor 512 further measures a third static fluid pressure as the needle 130 penetrates the tissue to a predetermined depth when the aperture 134 in the needle 130 (shown in Figures 1-3) becomes occluded. The sensor 512 also determines the static fluid pressure change between the second and third pressure (another increase in pressure) to indicate that the needle 130 has reached the predetermined depth. The fluid pressure increase occurs as the aperture as well as the needle lumen becomes occluded.

[0050] An example of a fluid pressure measurement assembly 500 that may be utilized with the present invention is a disposable fluid pressure monitoring system manufactured by Utah Medical Products, Inc. The assembly 500 may easily be attached to a luer lock attached to the proximal end of the needle 130. The disposable fluid pressure monitoring system provides fluid path visualization. Different manufacturers may also produce similar fluid pressure measurement systems that are capable of being utilized in the context of the present invention. Alternatively, a much smaller fluid pressure sensor assembly can be integrated directly into the needle assembly. For example, a smaller version of the sensor 512 could be mounted onto a small plastic connector that is used to attach the needle to the syringe.

[0051] In one embodiment, the fluid pressure measurement assembly 500 incorporates a visual feedback system such as the indicator 900 shown in Figure 9 to allow the operator to monitor the penetration depth of the needle 130. A signal processor can be included for use with the visual feedback system. In one embodiment, the signal processor uses a differentiating amplifier 800 (shown in Figure 8) to detect an increase in pressure (e.g., by using a transducer output voltage). The signal processor determines the initial pressure of the fluid dispensed in the needle 130 and determines the changes (or alternatively, rate of changes) in pressure caused by occlusion to the needle tip 132 lumen and/or the aperture 134. In one embodiment, the signal processor may cause the visual

-14-

indicator 900 to show a window 902 to indicate that the needle 130 has not reached the tissue and to give the operator the “go” signal to advance the needle 130. The “go” signal may be indicated when the pressure of the fluid remains relatively the same as the initial pressure of the fluid. In other words, there is no significant change in the pressure of the fluid. The magnitude of the change in the pressure of the fluid may be predetermined as shown in Figures 4-5.

Alternatively, the “go” signal may be indicated when there is no significant change in the rate of change of the fluid pressure. In one embodiment, when the magnitude of change in pressure, or alternatively, the rate of change in pressure, is insignificant, the signal processor causes the visual indicator 900 to show the window 902 to signal the operator to advance the needle 130.

[0052] Next, the signal processor may cause the visual indicator 900 to show a window 904 to indicate that the needle 130 has penetrated the tissue and the needle tip 132 lumen is occluded. The window 904 may be used to indicate that the change in the pressure of the fluid is significant and correlates to the penetration depth of the needle 130 where the needle tip 132 lumen is occluded by the tissue. The magnitude of the increase may be predetermined as shown in Figures 4-5. The magnitude of the increase in pressure as the needle tip 132 lumen is occluded is significantly larger than the magnitude of the increase in the pressure when the tissue has not occluded the lumen. Alternatively, the window 904 may be used to indicate that the rate of change in the pressure of the fluid is significant and correlates to the penetration depth of the needle 130 where the needle tip 132 lumen is occluded by the tissue. Based on an assessment of the magnitude of the increase in pressure, or alternatively, the rate of change in pressure, the signal processor may cause the window 904 to indicate to the operator to proceed with the advancement of the needle 130 slowly.

[0053] Next, the signal processor may cause the visual indicator 900 to show a window 906 to indicate that the needle 130 has penetrated the tissue to the predetermined distance and that the needle tip 132 lumen as well as the aperture

-15-

134 is occluded. The window 906 may be used to indicate that the change in the pressure of the fluid is dramatic or significant and correlates to the penetration depth of the needle 130 where the needle tip 132 lumen as well as the aperture 134 is occluded by the tissue. The magnitude of the increase may be predetermined as shown in Figures 4-5. The magnitude of the increase in pressure as the needle tip 132 lumen is occluded is significantly larger than the magnitude of the increase in the pressure when the tissue has occluded the needle tip 132 lumen. Alternatively, the window 906 may be used to indicate that the rate of change in the pressure of the fluid is dramatic or significant and correlates to the penetration depth of the needle 130 where the needle tip 132 lumen as well as the aperture 134 is occluded by the tissue. Based on an assessment of the magnitude of the increase in pressure, or alternatively, the rate of change in pressure, the signal processor may cause the window 906 to indicate to the operator to stop the advancement of the needle 130 because the penetration depth has been achieved.

[0054] In an alternative embodiment, an audible feedback system is incorporated into the pressure measurement assembly 500 instead of or in addition to the visual feedback system. The audible feedback system may be incorporated similarly to the visual feedback system previously described. Instead of having the visual indicator 900, the sensor 512 may incorporate a convenient audible feedback system. In one embodiment, the audible feedback system is recognizable by human such as a beeping sound. A slow beep may be used to indicate that the needle is filled with a fluid but has not reached the tissue. A faster beep may be used to indicate that the needle tip has penetrated the tissue and has become occluded. An even faster beep may be used to indicate that the needle 130 has reached the predetermined depth of the aperture and that the operator may stop.

[0055] In an alternative embodiment, a computer processor (not shown) is coupled to the pressure measurement assembly 500 to measure, calculate, and

-16-

assess the change or rate of change in the fluid pressure (dynamic or static) in the needle 130. In one embodiment, the computer processor is configured to use the differential amplifier 800 shown in Figure 8 to measure the rate of changes in pressure of the fluid dispensed in the needle 130. The computer processor is also configured to determine and distinguish the rate of changes in the pressure to determine and distinguish the various penetration depths of the needle 130. The computer processor is also coupled to the visual feedback system indicator 900 and/or the audible feedback system to issue various human-recognizable signals (e.g., visual indicator and audible indicator) to the operator as to the positions or penetration depths of the needle 130.

[0056] Figure 7 illustrates a front view of an alternative embodiment of a pressure measurement assembly 600 connected to the proximal end of the needle 130. The pressure measurement assembly 600 includes a signal processor and pressure display 610. Here, a proximal end of a bifurcated connector 616 has a transducer port 620 and a connection port 622 that connects the bifurcated connector 616 to the syringe 618. The needle 130 is connected to a distal end of the bifurcated connector 616. The syringe 618 is placed on a syringe pump 612.

[0057] The syringe pump 612 pumps a therapeutic agent at a constant rate through the needle 130. The therapeutic agent should be pumped very slowly so that the amount of therapeutic agent that is dispensed before the needle reaches the desired penetration depth is minimized. As the needle 130 advances and its tip makes contact with or penetrates tissue, the occlusion of the needle tip creates a first resistance to the flow of the therapeutic agent. This is detected by the pressure sensor 624. Accordingly, the increase in pressure indicates that the needle 130 has contacted tissue.

[0058] The operator continues to advance the needle 130 until the tissue begins to occlude the aperture (shown in Figures 1-3) of the needle 130. As the aperture becomes fully occluded, this increases the resistance to the flow of the

-17-

therapeutic agent and results in a second pressure increase as shown in region C in Figure 4.

[0059] In an alternative embodiment, a handheld syringe 618 or another suitable device is used to dispense a therapeutic agent into the needle 130 prior to inserting the needle 130 into the patient. The initial static fluid pressure of the therapeutic agent is measured. As the needle 130 advances and its tip lumen makes contact with or penetrates tissue, the occlusion of the needle tip lumen creates an increase in the static fluid pressure of the therapeutic agent. This is detected by the pressure sensor 624. Accordingly, the increase in pressure indicates that the needle 130 has contacted tissue. The operator continues to advance the needle 130 until the tissue begins to occlude the aperture (shown in Figures 1-3) of the needle 130. As the aperture becomes fully occluded, the static fluid pressure of the therapeutic agent increases even more. In the embodiments where the aperture correlates to the desired penetration depth for the needle, the last increase in fluid pressure indicates that the needle 130 has reached the desired penetration depth.

[0060] Figure 10 illustrates a side cross-sectional view of an alternative embodiment of a fluid delivery catheter 800 including an attached strain gauge 840. Similar to Figure 1, the fluid delivery catheter 800 includes a needle 830 within a needle sheath 810. The needle sheath 810 is attached to a dilatation catheter 820. The dilatation catheter 820 is delivered into the body over a guidewire 814 that guides the dilatation catheter 820 through tortuous pathways within a patient's body to a desired region or body cavity 860. The dilatation catheter 820 may include a balloon 812 that inflates and directs the distal end of the needle sheath 810 and needle 830 toward a vessel wall 850. The operator pushes the needle 830 toward the vessel wall 850 so that a needle tip 832 contacts the vessel wall 850. The needle 830 continues to move into the vessel wall 850 until a predetermined depth is reached. Here, the predetermined depth is reached when the distal portion of the strain gauge 840 contacts the vessel wall

850. As shown in Figure 7, the strain gauge 840 includes leads 844 extending from the strain gauge 840 to the proximal end of the needle.

[0061] An example of a strain gauge 840 that may be utilized with the present invention is a miniature semiconductor strain gauge manufactured by Entran. These strain gauges may be processed from P-type silicon in orientation, which provide maximum sensitivity to applied strain. Different strain gauges may also be available in other configurations. Different manufacturers may also produce similar strain gauges that are capable of being utilized in the present invention. In order to prevent false signals, the signal from the strain gauge should be offset or calibrated to the appropriate level of force that the tissue is expected to exert during successful tissue penetration. The force exerted by the tissue after successful needle penetration is much greater and longer in duration than accidental contact with the needle sheath, catheter assembly or vessel wall. To minimize false signals further, the force measurements should be taken only after the fluid delivery catheter 700 has reached its intended destination.

[0062] Figures 10A and 10B illustrate the embodiment of the fluid delivery catheter 800 of Figure 10 in different positions with respect to the vessel wall 850. Figure 10A illustrates the fluid delivery catheter 800 where the needle 830 has not yet contacted the vessel wall 850. The needle tip 832 is close to and proximate to but not contacting the vessel wall 850.

[0063] Figure 10B illustrates the fluid delivery catheter 800 where a portion of the needle tip 832 is contacting and has become embedded in the vessel wall 850. The needle 830 is inserted a predetermined depth into the vessel wall 850. As seen in Figure 7, the strain gauge 840 is attached to the needle 830 at a predetermined distance from the needle tip 832. When the needle 830 penetrates the vessel wall 850 to a predetermined depth, the strain gauge contacts the vessel wall 850 and senses contact pressure from the tissue. The contact pressure of the tissue thus signals to the operator that a certain penetration depth of the needle 830 has been achieved.

[0064] Figure 11 illustrates an enlarged view of the embodiment of the needle 830 and strain gauge 840 shown in Figure 10. The strain gauge 840 is shown attached to the needle 830 a predetermined distance from the needle tip 832. This allows the needle 830 to be inserted into the vessel wall or tissue to a predetermined penetration depth. In one embodiment, the predetermined depth is 0.5 to 3 millimeters. In one embodiment, as shown in Figure 11, the strain gauge 840 is covered by an encapsulant 842 to protect the strain gauge 840.

[0065] Strain gauges are typically mounted very securely to the item that is expected to deform or experience strain. Since the needle 830 is relatively strong, it will not deform during tissue penetration and the securely mounted strain gauge 840 will not produce a signal. In one embodiment, the strain gauge is embedded in a soft polymeric encapsulant 842 before it is mounted on the needle 830. When the soft encapsulant 842 makes contact with tissue during penetration, it deforms and transfers this energy to the strain gauge 840. In one embodiment, the soft polymeric material encapsulant 842 may be made of silicone. In alternative embodiments, the encapsulant 842 may be made of other biocompatible materials.

[0066] Figure 12A illustrates an enlarged view of an alternative embodiment of a needle 830 used in the fluid delivery catheter shown in Figure 10. Here, the needle 830 has a stepped design with a distal (first) portion 834 and a proximal (second) portion 836. The needle tip is 832 is located on the distal portion 834. The distal portion 834 has a smaller diameter than the proximal portion 836. In one embodiment, the distal portion 832 has an outer diameter of 0.008 to 0.26 inches.

[0067] Figure 12B illustrates an enlarged view of an alternative embodiment of a piezoelectric transducer 840 for use in the fluid delivery catheter as shown in Figure 10. The piezoelectric transducer 840 is shown with leads 844. This piezoelectric transducer 840 is also seen in conjunction with the needle 830 in Figure 12C. As seen in Figure 12C, the piezoelectric transducer 840 is located

-20-

on the stepped portion of the needle between distal portion 834 and the proximal portion 836 of the needle 830. The encapsulant 842 is located around the piezoelectric transducer 840. The stepped needle design is not necessary but may help to support the piezoelectric transducer 840 and improve manufacturability.

[0068] In one embodiment, the distal portion 834 of the needle 830 may have an outer diameter of 0.008 to 0.26 inches and a proximal portion diameter of 0.012 to 0.3 inches. In alternative embodiments, these dimensions may change according to application.

[0069] Figure 13 illustrates a side view of one embodiment of a piezoelectric transducer with a tubular shape 1040 connected to the needle 1030. The piezoelectric transducer 1040 is located a predetermined distance from the needle tip 1032 so that an operator may detect when the needle 1030 has reached the desired penetration depth in the tissue.

[0070] In one embodiment the piezoelectric transducer 1040 may also be covered by a soft encapsulant material as was shown for the strain gauge discussed above in reference to Figures 10-12. In an alternative embodiment, the piezoelectric transducer may not be covered by the encapsulant material.

[0071] Figure 14 illustrates the flow chart of one embodiment of a process 1100 of detecting tissue contact and needle penetration depth. At processing block 1110 the syringe dispenses a therapeutic agent through the needle.

[0072] At processing block 1120, the needle dispenses a measured amount of therapeutic agent from a second end of a needle to a first end of the needle. At processing block 1130, the dynamic injection pressure of the therapeutic agent in the needle is measured. At processing block 1140, a first increase in the dynamic injection pressure is measured when the first end of the needle contacts tissue. At processing block 1150, a second increase in the dynamic injection pressure is measured as the needle penetrates into the tissue to a predetermined depth.

[0073] Figure 15 illustrates the flow chart of one embodiment of a process 1500 of detecting tissue contact and needle penetration depth. At processing block 1502 the syringe dispenses a therapeutic agent into the needle. Once the therapeutic agent has filled the needle, the therapeutic agent is not dispensed continuously as the needle is inserted into the tissue.

[0074] At processing block 1504, an initial static pressure of the therapeutic agent is measured with the therapeutic agent not flowing through the needle at this point. At processing block 1506, a first change in the static pressure of the therapeutic agent is measured when the needle tip lumen contacts and becomes occluded by the tissue. At processing block 1508, a second change in the pressure of the therapeutic agent is measured when the needle aperture becomes occluded as the needle penetrates the tissue to a predetermined depth.

[0075] Systems and methods for detecting tissue contact and needle penetration depth have been described. Although the present invention has been described with reference to specific exemplary embodiments, it will be evident that various modifications and changes may be made to these embodiments without departing from the scope of the invention. Accordingly, the specification and drawings are to be regarded in an illustrative rather than a restrictive sense.

CLAIMS

What is claimed is:

1. A system for detecting tissue contact and penetration depth comprising:
 - a needle with a first end and a second end, said needle having a lumen and at least one aperture located a predetermined distance from said first end;
 - a fluid pressure measurement assembly coupled with a portion of said needle to measure pressure of a fluid dispensed in said needle, said pressure measurement assembly measuring a first pressure with said fluid dispensed in said needle, a second pressure when said needle contacts tissue and occludes said lumen before said aperture becomes occluded and a third pressure as said needle penetrates tissue and said aperture becomes occluded.
2. The system of claim 1 wherein said pressure measurement assembly comprising:
 - a fluid pressure sensor.
3. The system of claim 1 wherein said pressure of fluid includes a pressure of a therapeutic agent to be injected into said tissue.
4. The system of claim 1 wherein said pressure of fluid is a static pressure.
5. The system of claim 1 wherein said aperture has an area in said range between about 0.003 and 10 mm².
6. The system of claim 1 wherein said predetermined distance is a desired penetration depth of said needle into said tissue.

-23-

7. The system of claim 5 wherein said predetermined distance from said first end is about 0.5 to 10 millimeters.

8. The system of claim 1 wherein said first end of said needle has at least one of a tapered and untapered portion.

9. The system of claim 1 wherein said needle has an outer diameter in said range between about 0.008 and 0.26 inches.

10. The system of claim 1 wherein said needle has an inner diameter in said range between about 0.004 and 0.22 inches.

11. The system of claim 1 further comprises a computer processor coupling to said fluid pressure measurement assembly, said computer processor configured to perform at least one of determining and distinguishing said rate of changes in said static pressure to determine and distinguish said various penetration depths of said needle.

12. The system of claim 11 wherein said computer processor further couples to at least one of a visual feedback system indicator and an audible feedback system to issue human-recognizable signals as to penetration depths of said needle.

13. A method of detecting tissue contact and a needle penetration depth of a needle used internally to deliver a therapeutic agent to a patient comprising:
filling a needle with a therapeutic agent;
measuring a pressure of said therapeutic agent in said needle;
measuring a first change in pressure when said needle contacts tissue at a needle tip lumen; and

-24-

measuring a second change in pressure when said needle penetrates said tissue and occludes an aperture located a predetermined distance from said needle tip.

14. The method of claim 13 further comprises indicating said first change in said pressure and said second change in said pressure using at least one of a visual feedback scheme and an audible feedback scheme.

15. The method of claim 13 wherein measuring pressure of said therapeutic agent in said needle includes measuring pressure of said therapeutic agent using a fluid pressure measurement assembly.

16. The method of claim 13 wherein measuring said pressure of said therapeutic agent in said needle includes measuring a static fluid pressure of said therapeutic agent using a pressure measurement assembly.

17. The method of claim 13 wherein said therapeutic agent is one of a drug, growth factor, and gene therapy.


18. The method of claim 13 wherein said predetermined depth ranges between 0.5 and 10 millimeters.


19. The method of claim 14 wherein indicating said first change in pressure includes an indication to alert that said needle contacts said tissue and indicating said second change in pressure includes an indication to alert that said needle penetrates said tissue said predetermined distance.

20. The method of claim 12 wherein a computer processor coupling to a pressure measurement assembly determines rate of changes in said pressure to

-25-

aid in measuring said pressure of said therapeutic agent in said needle, measuring said first change in pressure when said needle contacts tissue at a needle tip lumen, and measuring said second change in pressure when said needle penetrates said tissue and occludes said aperture located said predetermined distance from said needle tip.












FIG. 2A



5/16

Figure 4
Fluid Injection Pressure
 Saline, 0.002" Aperture 1 mm Proximal to Needle Tip



6/16




FIGURE 5

7/16




FIG. 6







FIG. 7

9/16

FIGURE 8FIGURE 9

10/16






FIG. 10B




FIG. 10A

12/16




FIG. 11

13/16




Figure 12A

Figure 12B





Figure 12C

14/16






FIG. 13

15/16

1100**FIG. 14**

16/16

**FIG. 15**

INTERNATIONAL SEARCH REPORT

International Application No
T/US2004/027961

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61M5/46		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61M		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 302 870 B1 (DAVIS CLARK C ET AL) 16 October 2001 (2001-10-16) abstract -----	1
A	US 4 299 230 A (KUBOTA TETSUMARU) 10 November 1981 (1981-11-10) abstract column 2, lines 18-40; figures 1,2 column 4, lines 24-48; figure 11 -----	1
A	US 6 391 005 B1 (MELTON JR HEWLETT E ET AL) 21 May 2002 (2002-05-21) abstract -----	1
A	DE 44 20 232 A (WALTEREIT ROBERT) 14 December 1995 (1995-12-14) abstract -----	1
-/--		
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents :</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>* & * document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">3 December 2004</div>		Date of mailing of the international search report <div style="text-align: center;">16/12/2004</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center;">Nielsen, M</div>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/027961

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 470 316 A (AUTRY SIDNEY D ET AL) 28 November 1995 (1995-11-28) abstract	1
A	US 6 217 554 B1 (GREEN BERT) 17 April 2001 (2001-04-17) abstract	1
A	US 6 494 862 B1 (BHAT VINAYAK D ET AL) 17 December 2002 (2002-12-17) abstract	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/027961

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-20
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

US2004/027961

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6302870	B1	16-10-2001	AU 4804300 A EP 1173240 A1 JP 2002542901 T WO 0066199 A1	17-11-2000 23-01-2002 17-12-2002 09-11-2000
US 4299230	A	10-11-1981	US 4356826 A	02-11-1982
US 6391005	B1	21-05-2002	DE 19914485 A1 GB 2335990 A JP 11309124 A US 2002042594 A1	18-11-1999 06-10-1999 09-11-1999 11-04-2002
DE 4420232	A	14-12-1995	DE 4420232 A1	14-12-1995
US 5470316	A	28-11-1995	NONE	
US 6217554	B1	17-04-2001	NONE	
US 6494862	B1	17-12-2002	US 6283947 B1 AU 2730401 A WO 0149357 A2 US 2003040712 A1 US 2001007059 A1	04-09-2001 16-07-2001 12-07-2001 27-02-2003 05-07-2001